Cargando…

Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study

BACKGROUND: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunode...

Descripción completa

Detalles Bibliográficos
Autores principales: Boulware, David R., Meya, David B., Bergemann, Tracy L., Wiesner, Darin L., Rhein, Joshua, Musubire, Abdu, Lee, Sarah J., Kambugu, Andrew, Janoff, Edward N., Bohjanen, Paul R.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014618/
https://www.ncbi.nlm.nih.gov/pubmed/21253011
http://dx.doi.org/10.1371/journal.pmed.1000384
_version_ 1782195361004126208
author Boulware, David R.
Meya, David B.
Bergemann, Tracy L.
Wiesner, Darin L.
Rhein, Joshua
Musubire, Abdu
Lee, Sarah J.
Kambugu, Andrew
Janoff, Edward N.
Bohjanen, Paul R.
author_facet Boulware, David R.
Meya, David B.
Bergemann, Tracy L.
Wiesner, Darin L.
Rhein, Joshua
Musubire, Abdu
Lee, Sarah J.
Kambugu, Andrew
Janoff, Edward N.
Bohjanen, Paul R.
author_sort Boulware, David R.
collection PubMed
description BACKGROUND: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood and prediction of IRIS is not possible. METHODS AND FINDINGS: We prospectively followed 101 ART-naïve Ugandans with AIDS and recent CM for one year after initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS) manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21% without IRIS. CM-IRIS was independently associated with death (HR = 2.3, 95% CI 1.1–5.1, p = 0.04). Patients experiencing subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p = 0.006). Higher pre-ART levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted future IRIS in multivariate analyses (area under the curve [AUC] = 0.82). An algorithm based on seven pre-ART serum biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with increasing hazard of IRIS by time-to-event analysis (each p≤0.001). At the time of IRIS onset, multiple proinflammatory cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing GM-CSF, and CRP level >32 mg/l (highest quartile). Pre-ART CRP level >32 mg/l alone was associated with future death (OR = 8.3, 95% CI 2.7–25.6, p<0.001). CONCLUSIONS: Pre-ART increases in Th(17) and Th(2) responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses (e.g., TNF-α, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions. Please see later in the article for the Editors' Summary
format Text
id pubmed-3014618
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30146182011-01-20 Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study Boulware, David R. Meya, David B. Bergemann, Tracy L. Wiesner, Darin L. Rhein, Joshua Musubire, Abdu Lee, Sarah J. Kambugu, Andrew Janoff, Edward N. Bohjanen, Paul R. PLoS Med Research Article BACKGROUND: Although antiretroviral therapy (ART) improves survival in persons with cryptococcal meningitis (CM) and AIDS, ART frequently elicits HIV immune reconstitution inflammatory syndrome (IRIS), an exaggerated and frequently deadly inflammatory reaction that complicates recovery from immunodeficiency. The pathogenesis of IRIS is poorly understood and prediction of IRIS is not possible. METHODS AND FINDINGS: We prospectively followed 101 ART-naïve Ugandans with AIDS and recent CM for one year after initiating ART, and used Luminex multiplex assays to compare serum cytokine levels in participants who did or did not develop IRIS. IRIS occurred in 45% of participants with recent CM on ART, including 30% with central nervous system (CNS) manifestations. The median time to CM-IRIS was 8.8 wk on ART. Overall mortality on ART was 36% with IRIS and 21% without IRIS. CM-IRIS was independently associated with death (HR = 2.3, 95% CI 1.1–5.1, p = 0.04). Patients experiencing subsequent CM-IRIS had 4-fold higher median serum cryptococcal antigen (CRAG) levels pre-ART (p = 0.006). Higher pre-ART levels of interleukin (IL)-4 and IL-17 as well as lower tumor necrosis factor (TNF)-α, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and vascular endothelial growth factor (VEGF) predicted future IRIS in multivariate analyses (area under the curve [AUC] = 0.82). An algorithm based on seven pre-ART serum biomarkers was a robust tool for stratifying high (83%), moderate (48%), and low risk (23%) for IRIS in the cohort. After ART was initiated, increasing levels of C-reactive protein (CRP), D-dimer, IL-6, IL-7, IL-13, G-CSF, or IL-1RA were associated with increasing hazard of IRIS by time-to-event analysis (each p≤0.001). At the time of IRIS onset, multiple proinflammatory cytokine responses were present, including CRP and IL-6. Mortality was predicted by pre-ART increasing IL-17, decreasing GM-CSF, and CRP level >32 mg/l (highest quartile). Pre-ART CRP level >32 mg/l alone was associated with future death (OR = 8.3, 95% CI 2.7–25.6, p<0.001). CONCLUSIONS: Pre-ART increases in Th(17) and Th(2) responses (e.g., IL-17, IL-4) and lack of proinflammatory cytokine responses (e.g., TNF-α, G-CSF, GM-CSF, VEGF) predispose individuals to subsequent IRIS, perhaps as biomarkers of immune dysfunction and poor initial clearance of CRAG. Although requiring validation, these biomarkers might be an objective tool to stratify the risk of CM-IRIS and death, and could be used clinically to guide when to start ART or use prophylactic interventions. Please see later in the article for the Editors' Summary Public Library of Science 2010-12-21 /pmc/articles/PMC3014618/ /pubmed/21253011 http://dx.doi.org/10.1371/journal.pmed.1000384 Text en Boulware et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Boulware, David R.
Meya, David B.
Bergemann, Tracy L.
Wiesner, Darin L.
Rhein, Joshua
Musubire, Abdu
Lee, Sarah J.
Kambugu, Andrew
Janoff, Edward N.
Bohjanen, Paul R.
Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title_full Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title_fullStr Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title_full_unstemmed Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title_short Clinical Features and Serum Biomarkers in HIV Immune Reconstitution Inflammatory Syndrome after Cryptococcal Meningitis: A Prospective Cohort Study
title_sort clinical features and serum biomarkers in hiv immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3014618/
https://www.ncbi.nlm.nih.gov/pubmed/21253011
http://dx.doi.org/10.1371/journal.pmed.1000384
work_keys_str_mv AT boulwaredavidr clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT meyadavidb clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT bergemanntracyl clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT wiesnerdarinl clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT rheinjoshua clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT musubireabdu clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT leesarahj clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT kambuguandrew clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT janoffedwardn clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy
AT bohjanenpaulr clinicalfeaturesandserumbiomarkersinhivimmunereconstitutioninflammatorysyndromeaftercryptococcalmeningitisaprospectivecohortstudy